Trifecta生物瓣中期随访早期结构衰败的单中心研究
该单中心回顾性研究分析了2011至2016年2807例主动脉瓣生物瓣置换,比较Trifecta与Perimount、Perimount Magna Ease及Mitroflow瓣膜的表现。Trifecta瓣早期结构衰败发生率显著高于其他瓣膜,平均衰败时间4.5±1.7年,未发现患者或瓣膜相关原因。
要点
- Trifecta瓣早期结构衰败率显著高于Perimount、Perimount Magna Ease和Mitroflow瓣。
- 衰败时71%的Trifecta瓣存在中度或重度反流,平均峰值压差61±29 mmHg。
- 未识别出与Trifecta瓣早期衰败相关的患者或瓣膜因素。
核心结论
- Trifecta生物瓣早期结构衰败发生率增加,显著高于Perimount、Perimount Magna Ease或Mitroflow瓣。
- 未发现患者相关或瓣膜相关的衰败原因。
研究设计与样本
- 回顾性单中心研究,纳入2011至2016年所有生物瓣主动脉瓣置换手术,共2807例。
- 比较Trifecta瓣(836例)与Perimount(1031例)、Perimount Magna Ease(449例)及Mitroflow(351例)瓣膜的表现。
- 分析失败瓣膜中患者相关和瓣膜相关的早期衰败危险因素。
主要发现
- 24例Trifecta瓣发生早期结构衰败,显著高于Perimount(无衰败,P < .001)和Perimount Magna Ease(无衰败,P < .005)。
- Trifecta瓣衰败数显著高于Mitroflow瓣(1例衰败,P < .05)。
- 感染性心内膜炎或死亡发生率无差异。
- 瓣膜衰败时,17例(71%)Trifecta瓣存在中度或重度反流,平均峰值压差61 ± 29 mm Hg。
- 衰败瓣膜中位尺寸为23 mm,1例失败瓣膜存在严重患者- prosthesis不匹配,平均衰败时间4.5 ± 1.7年。
临床怎么用
- 对于植入Trifecta生物瓣的患者,中期随访需警惕早期结构衰败,尤其是反流和压差升高。
- 临床决策中选择主动脉瓣生物瓣时,应权衡Trifecta瓣早期衰败风险。
局限性
- 本研究为单中心回顾性研究,可能存在选择偏倚。
- 未识别出患者或瓣膜相关衰败原因,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A cluster of aortic bioprosthetic valve failures, most of which were Trifecta bioprostheses, was observed in Southampton General Hospital, Southampton, United Kingdom. This study was performed to assess whether the cluster represents a significant failure of this valve model or whether there is a selection bias that can explain the failure of these valves. METHODS: This retrospective study evaluated all bioprosthetic aortic valve replacement operations performed between 2011 and 2016 inclusive in our center. The study compared the performance of the Trifecta valve (Abbott, Abbott Park, IL) with that of Perimount (Edwards Lifesciences, Irvine, CA), Perimount Magna Ease, and Mitroflow (LivaNova, London, United Kingdom) bioprostheses. In addition, the study analyzed patient-related and valve-related risk factors for early failure in the failed valves. RESULTS: A total of 2807 bioprosthetic aortic valve replacements were performed. Of these, 836 were Trifecta valves, 1031 were Perimount, 449 were Perimount Magna Ease, and 351 were Mitroflow valves. A total of 24 Trifecta valves had premature structural failure, a number significantly higher than seen with Perimount or Perimount Magna Ease (no failure, P < .001 and P < .005, respectively) valves and the Mitroflow valve (1 failure, P < .05). There was no difference in the incidence of endocarditis or death. At the time of valve failure, 17 (71%) of the failed Trifecta valves had moderate or severe regurgitation, and the average peak gradient was 61 ± 29 mm Hg. The median failed prosthetic size was 23 mm. One failed valve had severe patient-prosthesis mismatch. The mean time to failure was 4.5 ± 1.7 years. CONCLUSIONS: The Trifecta bioprosthesis has an increased incidence of early structural valve failure, which is significantly higher than that of Perimount, Perimount Magna Ease, or Mitroflow. No patient-related or valve-related cause for the failure could be identified.
引用
- Kattach H, Shah BN, Harden S, et al. Premature Structural Failure of Trifecta Bioprosthesis in Midterm Follow-up: A Single-Center Study. Ann Thorac Surg. 2020. PMID: 33338482. doi:10.1016/j.athoracsur.2020.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。